DOI QR코드

DOI QR Code

Sjögren Syndrome after Radioiodine Therapy in Thyroid Cancer Patients

  • Lee, Hee Jin (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry) ;
  • Kim, Jae-Jeong (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry) ;
  • Kim, Young-Gun (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry) ;
  • Ahn, Hyung-Joon (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry) ;
  • Choi, Jong-Hoon (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry) ;
  • Kwon, Jeong-Seung (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentistry)
  • Received : 2018.06.15
  • Accepted : 2018.07.10
  • Published : 2018.09.30

Abstract

Salivary and lacrimal gland dysfunction is relatively frequent after radioiodine therapy. In most cases this is a transient side effect, but in some patients it may persist for a long period or appear late. Radioiodine ($^{131}I$) therapy is often administered to patients following total thyroidectomy to treat well-differentiated follicular cell-derived thyroid cancer. In addition to the thyroid, $^{131}I$ accumulates in the salivary glands, giving rise to transient or permanent salivary gland damage. Salivary gland dysfunction following radioiodine therapy can be caused by radiation damage. But, it also may be associated with $Sj{\ddot{o}}gren$ syndrome (SS) developed after radioiodine therapy. It would be recommended that the evaluation for SS including anti-SSA/Ro and anti-SSB/La should be considered before and after radioiodine therapy.

Keywords

References

  1. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738-743.
  2. Fox RI, Saito I. Sjogren's syndrome. Autoimmune Diseases of the Skin: Springer; 2005. pp. 261-289.
  3. Gheita TA, Fawzy SM, Kandeel AA, Khalil HM. Sjogren syndrome and fibromyalgia after radioiodine therapy in cancer thyroid patients. Egypt Rheumatol 2011;33:107-112. https://doi.org/10.1016/j.ejr.2011.03.007
  4. Hollingsworth B, Senter L, Zhang X, et al. Risk factors of 131iinduced salivary gland damage in thyroid cancer patients. J Clin Endocrinol Metab 2016;101:4085-4093. https://doi.org/10.1210/jc.2016-1605
  5. Markitziu A, Lustmann J, Uzieli B, Krausz Y, Chisin R. Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer. Oral Surg Oral Med Oral Pathol 1993;75:318-322. https://doi.org/10.1016/0030-4220(93)90144-S
  6. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1996;21:780-782. https://doi.org/10.1097/00003072-199610000-00006
  7. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554.
  8. Cavalieri RR. Iodine metabolism and thyroid physiology: current concepts. Thyroid 1997;7:177-181. https://doi.org/10.1089/thy.1997.7.177
  9. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 2002;27:767-771. https://doi.org/10.1097/00003072-200211000-00003
  10. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558. https://doi.org/10.1136/ard.61.6.554
  11. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76:9-16. https://doi.org/10.1136/annrheumdis-2016-210571
  12. Franceschini F, Cavazzana I, Andreoli L, Tincani A. The 2016 classification criteria for primary Sjogren's syndrome: what's new? BMC Med 2017;15:69. https://doi.org/10.1186/s12916-017-0837-1
  13. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996;35:535-540.
  14. Vini L, Harmer C. Radioiodine treatment for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2000;12:365-372. https://doi.org/10.1053/clon.2000.9196
  15. Kang JY, Jang SJ, Lee WW, Jang SJ, Lee YJ, Kim SE. Evaluation of salivary gland dysfunction using salivary gland scintigraphy in Sjogren's syndrome patients and in thyroid cancer patients after radioactive iodine therapy. Nucl Med Mol Imaging 2011;45:161-168. https://doi.org/10.1007/s13139-011-0091-y
  16. Mandel L, Liu F. Salivary gland injury resulting from exposure to radioactive iodine: case reports. J Am Dent Assoc 2007;138:1582-1587. https://doi.org/10.14219/jada.archive.2007.0107
  17. Zettinig G, Hanselmayer G, Fueger BJ, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a crosssectional study. Eur J Nucl Med Mol Imaging 2002;29:1428-1432. https://doi.org/10.1007/s00259-002-0969-0
  18. Burns JA, Morgenstern KE, Cahill KV, Foster JA, Jhiang SM, Kloos RT. Nasolacrimal obstruction secondary to I(131) therapy. Ophthalmic Plast Reconstr Surg 2004;20:126-129. https://doi.org/10.1097/01.IOP.0000117340.41849.81
  19. Sakahara H, Yamashita S, Suzuki K, Imai M, Kosugi T. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer. Ann Nucl Med 2007;21:525-527. https://doi.org/10.1007/s12149-007-0056-5